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Glutamatergic dysfunction has been implicated in psychiatric disorders such as schizophrenia. The
stimulation of metabotropic glutamate (mGlu) 2 receptor has been shown to be effective in a number
of animal models of schizophrenia. In this study, we investigated the antipsychotic proﬁles of (2S)-5-
methyl-2-{[4-(1,1,1-triﬂuoro-2-methylpropan-2-yl)phenoxy]methyl}-2,3-dihydroimidazo[2,1-b][1,3]
oxazole-6-carboxamide (TASP0443294), a newly synthesized positive allosteric modulator of the
mGlu2 receptor. TASP0443294 potentiated the response of human mGlu2 and rat mGlu2 receptors to
glutamate with EC50 values of 277 and 149 nM, respectively, without affecting the glutamate response
of human mGlu3 receptor. TASP0443294 was distributed in the brain and cerebrospinal ﬂuid
after peroral administration in rats. The peroral administration of TASP0443294 inhibited
methamphetamine-induced hyperlocomotion in rats, which was attenuated by an mGlu2/3 receptor
antagonist, and improved social memory impairment induced by 5R,10S-(þ)-5-methyl-10,11-dihydro-
5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate (MK-801) in rats. Furthermore,
TASP0443294 reduced the ketamine-induced basal gamma hyperactivity in the prefrontal cortex and
suppressed rapid eye movement (REM) sleep in rats. These ﬁndings indicate that TASP0443294 is an
mGlu2 receptor positive allosteric modulator with antipsychotic activity, and that the suppression of
aberrant gamma oscillations and REM sleep could be considered as neurophysiological biomarkers for
TASP0443294.
© 2015 Japanese Pharmacological Society. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
In addition to the dopamine hypothesis of schizophrenia, ab-
normalities in glutamatergic transmission have also been sug-
gested to be involved in the pathophysiology of schizophrenia.
Among glutamate receptors, metabotropic glutamate (mGlu) re-
ceptors, which consist of 8 subtypes (mGlu1-8), have emerged as
attractive therapeutic targets for the development of novel in-
terventions for psychiatric disorders.: þ81 48 652 7254.
hi).
acological Society.
Production and hosting by ElsevieOf the mGlu receptor subtypes, group II mGlu receptors, con-
sisting of mGlu2 and mGlu3 receptors, are primarily localized
presynaptically and are negatively coupled via Gi proteins to ade-
nylate cyclase, leading to the inhibition of glutamate release upon
neuronal activation (1). In addition, mGlu2 and mGlu3 receptors
are expressed postsynaptically and glial cells, respectively, where
they regulate glutamate transmission (2,3). These receptors have
been proposed to play important roles in the pathophysiology of
schizophrenia (4,5). Indeed, several potent dual mGlu2/3 receptor
agonists, which have structurally constrained analogs of glutamate,
have been identiﬁed, and a growing body of evidence has shown
that several mGlu2/3 receptor agonists exhibit antipsychotic ac-
tivity in numerous experimental animal models of schizophrenia
(4). Among mGlu2/3 receptors, the stimulation of the mGlu2r B.V. All rights reserved.
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mGlu2/3 receptor agonists in animal models for schizophrenia,
since the antipsychotic effects of mGlu2/3 receptor agonists are no
longer observed in mice lacking the mGlu2 receptor but not the
mGlu3 receptor (6,7). These mGlu2/3 receptor agonists bind at an
orthosteric binding site to which endogenous glutamate ligands
bind. On the other hand, positive allosteric modulators do not
activate the receptor directly, but act at an allosteric site on the
receptor to potentiate glutamate-induced activation and produce
their effects only in the presence of an endogenous ligand (gluta-
mate) (8), thereby reducing the risk of side effects and tolerance
related to continuous receptor stimulation with orthosteric ago-
nists. Therefore, allosteric modulators may offer advantages over
orthosteric agonists as therapeutic agents.
In this sense, selective positive allosteric modulators of mGlu2
receptor should be of interest and may provide an advantage over
orthosteric mGlu2/3 receptor agonists. Indeed, positive allosteric
modulators preferentially acting on the mGlu2 receptor over the
mGlu3 receptor reportedly exert antipsychotic effects in animal
models (9e12). Therefore, the selective stimulation of the mGlu2
receptor may be a useful approach for the treatment of schizo-
phrenia. However, some important differences exist in the effects of
mGlu2 receptor positive allosteric modulators in animal models
(10), with these differences possibly being ascribed to the differ-
ential actions of each compound on the mGlu2 receptor. Thus, an
investigation of the pharmacological proﬁles with structurally
distinct mGlu2 receptor positive allosteric modulators should
provide additional information regarding the usefulness of mGlu2
receptor positive allosteric modulators as antipsychotics. Recently,
we synthesized a structurally novel and orally active mGlu2 re-
ceptor positive allosteric modulator, (2S)-5-methyl-2-{[4-(1,1,1-
triﬂuoro-2-methylpropan-2-yl)phenoxy]methyl}-2,3-
dihydroimidazo[2,1-b][1,3]oxazole-6-carboxamide (TASP0443294)
(Fig. 1).
The aim of this study was to further support the assumptions
that the stimulation of mGlu2 receptors results in antipsychotic
effects using TASP0443294. Moreover, to evaluate the neurophys-
iological mechanisms of mGlu2 positive allosteric modulators, we
investigated the effects of TASP0443294 on ketamine-induced
basal gamma hyperactivity on electroencephalograms (EEG)
showing activity in the prefrontal cortex and on rapid eye move-
ment (REM) sleep on polysomnograms in rats.
2. Methods
2.1. Animals
Male SpragueeDawley andWistar rats (purchased from Charles
River, Yokohama, Japan) were used for this study. The rats were
housed in a controlled animal room (room temperature: 23 ± 3 C,
humidity: 50 ± 20%) with a 12-h lightedark cycle (lights on:Fig. 1. Chemical structure of TASP0443294.07:00e19:00). Rats were maintained in groups of 2 or 4 rats per
cage. Food and water were available ad libitum. All the studies were
conducted in accordance with the criteria of the Taisho Pharma-
ceutical Co., Ltd. Animal Care Committee and met the Japanese
Experimental Animal Research Association standards, as deﬁned in
the Guidelines for Animal Experiments (1987).
2.2. In vitro studies
2.2.1. Cell culture and membrane preparation
Chinese hamster ovary (CHO) cell lines stably expressing rat
mGlu2 receptor were kindly donated by Dr. Nakanishi (Kyoto Uni-
versity, Kyoto, Japan). CHO cell lines stably expressing humanmGlu
receptors (mGlu2, mGlu3 and mGlu8 receptor) were established in
house. The cells expressing mGlu2 or mGlu3 receptor were
cultured in Dulbecco's modiﬁed Eagle medium (DMEM) containing
10% dialyzed fetal bovine serum (FBS), 2 mM L-glutamine, 1% pro-
line, penicillin (50 units/mL for rat mGlu2 receptor,100 units/mL for
human mGlu2 and mGlu3 receptor expressed cells) and strepto-
mycin (50 mg/mL for rat mGlu2 receptor, 100 mg/mL for human
mGlu2 and mGlu3 receptor expressed cells), 1 mM sodium pyru-
vate, 1 mM succinic acid, 1 mM succinic acid disodium salt and
hygromycin B (400 mg/mL for human mGlu2, or 300 mg/mL for
human mGlu3 receptor expressed cells). The cells expressing hu-
manmGlu8 receptor were cultured in Ham's F-12 Nutrient Mixture
(F-12) containing 10% FBS, 100 U/mL penicillin, 100 mg/mL strep-
tomycin and 500 mg/mL G418. The cells were in an incubator
maintained at 37 C in a humidiﬁed atmosphere of 5% CO2.
Conﬂuent cells expressing each mGlu receptor were washed in
phosphate-buffered saline, scraped, and centrifuged at 190  g for
5 min at 4 C. The pellet was homogenized with 20 mM HEPES
buffer (pH 7.4) for mGlu2 receptor expressed cells or 20 mM HEPES
buffer containing 1mM EDTA (pH 7.4) for mGlu3 ormGlu8 receptor
expressed cells, then centrifuged at 48,000  g for 20 min at 4 C.
The pellet was washed twice and suspended with 20 mM HEPES
buffer or 20 mM HEPES buffer containing 1 mM EDTA (pH 7.4) to
obtain the crude membrane fraction, which was stored at 80 C.
2.2.2. [35S]GTPgS binding assay
The above mentioned membranes were diluted in 20 mM
HEPES buffer (pH 7.4), containing 1 mM EDTA (for mGlu3 and
mGlu8 receptor), 100 mM NaCl, 10 mM MgCl2, 8.4 mM GDP, 10 mg/
mL saponin, and 0.1% BSA to yield a protein concentration of 10 (for
mGlu2 and mGlu8 receptor) or 15 (for mGlu3 receptor) mg/assay.
Themembranes were pre-incubatedwith various concentrations of
TASP0443294 for 20 min at 30 C; subsequently, various concen-
trations of glutamate and [35S]GTPgS (0.15 nM) were added and the
membranes were further incubated for 60 min at 30 C. The reac-
tion was terminated by rapid ﬁltration under a vacuum through a
UniFilter GF/C microplate (PerkinElmer Life Science, Boston, MA,
USA), after which the ﬁlters were washed with 1 mL of ice-cold
20 mM HEPES buffer or 20 mM HEPES buffer containing 1 mM
EDTA (pH 7.4) using a UniFilter-96 harvester (PerkinElmer Life
Science, Boston, MA, USA). After drying the ﬁlters, 20 mL of
Microscint-O (PerkinElmer Life Science, Boston, MA, USA) was
added, and the membrane-bound radioactivity was counted with a
TopCount NXT™ (PerkinElmer Life Science, Boston, MA, USA). The
speciﬁc binding of [35S]GTPgS was calculated by subtracting the
nonspeciﬁc binding in the absence of glutamate. The amount of
[35S]GTPgS binding was normalized with the response to 1 mM
glutamate. The EC50 values of TASP0443294 for mGlu2 positive
allosteric modulator activity were determined in the presence of an
EC20-equivalent concentration of glutamate (1 mM for human
mGlu2 receptor or 3 mM for rat mGlu2 receptor). The effect
of TASP0443294 on human mGlu3 receptor was examined in
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100 nM.
2.2.3. Pharmacokinetics, and brain and plasma levels in rats
For the pharmacokinetic study, TASP0443294was intravenously
administered at 0.25 mg/kg to fasted male SpragueeDawley rats
(7 weeks old). Then blood samples were repeatedly collected
at several time points (5, 15, and 30 min and 1, 2, 4, 8, and 24 h)
after the administration of TASP0443294 from the tail vein using
EDTA as the anticoagulant. To evaluate the time course of the
plasma levels of TASP0443294 prior to the behavioral studies,
TASP0443294 was perorally administered at a dose of 3 mg/kg to
male Wistar rats (7 weeks old) and blood samples were then
collected at 0.5, 1, 2, and 3 h after the administration of
TASP0443294 from the tail vein using EDTA. To evaluate the brain,
plasma and cerebrospinal ﬂuid (CSF) levels after the systemic
administration of TASP0443294, TASP0443294 was administered
at doses of 3, 10, and 30 mg/kg perorally to male Wistar rats. Then,
the rats were sacriﬁced after collecting a blood sample at 2.5 h after
TASP0443294 administration, and the CSF and brain were rapidly
collected and removed, respectively. Plasma was obtained
following centrifugation, was subjected to protein precipitation,
and was subsequently analyzed for TASP0443294 using a liquid
chromatography/tandem mass spectrometry qualiﬁed research
method on an API4000 instrument (Applied Sciex, Foster City, CA,
USA). The pharmacokinetic parameters were calculated using
WinNonlin software (Pharsight Corporation, Mountain View, CA,
USA).
2.3. Behavioral studies
2.3.1. Locomotor activity
The locomotor activity of male Wistar rats (7 weeks old) was
measured using a SCANETapparatus (Melquest Ltd., Toyama, Japan)
according to previously reported methods (13). Rats were individ-
ually placed into the test chamber (47 cm width  28 cm
length  30 cm height), which in turn was placed in a soundproof
box, at 120 min after TASP0443294 administration. Spontaneous
locomotor activity was then measured for 60 min. In the drug
interaction study, the rats were individually habituated to the test
chamber placed in a soundproof box for 60 min, and metham-
phetamine was then subcutaneously administered at a dose of
1 mg/kg; the locomotor activities were immediately recorded for
120 min. TASP0443294 was administered perorally 120 min prior
to the methamphetamine administration. LY341495 was adminis-
tered intraperitoneally 60 min prior to the methamphetamine
administration. Under the same condition, peroral administration
of clozapine at doses of 30 and 100 mg/kg signiﬁcantly inhibited
methamphetamine-induced locomotor and rearing hyperactivities
in rats.
2.3.2. Social recognition test
The social recognition test was performed as described previ-
ously (14). The behavior tests were performed in an open-topped
box (47 cm width  28 cm length  30 cm height) containing
sawdust. Adult male SpragueeDawley rats (9 weeks old) were used
in this test because Wistar rats exhibited shorter interaction time
than SpragueeDawley rats. A rat was placed in the test cage and
was allowed to habituate for 30 min. Then, an unfamiliar juvenile
rat (4 weeks old) was placed in the test cage with the adult rat for
5 min (the ﬁrst test session). The length of time during which the
adult rat exhibited exploratory behavior (snifﬁng, grooming, and
close following) toward the juvenile rat during the test session was
recorded and was deﬁned as the ﬁrst investigation duration. The
juvenile was then removed from the test cage and returned to itshome cage, while the adult was left in the test cage. Thirty minutes
later, the same juvenile (familiar) was then placed in the test cage
once again for a 5-min test session (the second test session); the
length of time spent by the adult in exploring the juvenile during
this test session was deﬁned as the second investigation duration.
Observers who were blinded to the treatment group scored the
investigation duration (the ﬁrst and the second test sessions). The
social memory for each adult rat was deﬁned by determining the
ratio of the second investigation duration to the ﬁrst investigation
duration. MK-801 was administered intraperitoneally to the adult
rats 30 min prior to the ﬁrst exposure to the juvenile. TASP0443294
was administered perorally to the rats at 120 min prior to the MK-
801 administration. Under the same condition, intraperitoneal
administration of clozapine at a dose of 0.3 mg/kg but not halo-
peridol signiﬁcantly improved MK-801-induced social memory
deﬁcits in rats (14).
2.4. Quantitative electroencephalogram and polysomnogram
studies
2.4.1. Implantation of electrodes
To implant the electrodes for the quantitative electroencepha-
logram (qEEG) or polysomnogram recording, male SpragueeDaw-
ley rats (9e10 weeks old) were anaesthetized with pentobarbital
sodium (50 mg/kg, intraperitoneally) and ﬁxed in a stereotaxic
frame. After drilling holes in the skull, stainless steel screw elec-
trodes (E363/20; PlasticsOne, Roanoke, VA, USA) were placed on
the cerebral dura mater at positions according to a rat brain atlas
(15) as follows: the recording electrode was placed over the frontal
cortex at 1.5 mm anterior and 2.0 mm lateral from the bregma, the
reference electrode was placed over the cerebellum at 11.5 mm
posterior and 0 mm lateral from the bregma, and the ground
electrode was placed over the contralateral occipital cortex at
6.0 mm posterior and 2.0 mm lateral from the bregma. For the
polysomnogram recording, two stainless steel subcutaneous elec-
trodes (E363/76; PlasticsOne, Roanoke, VA, USA) with needles were
bipolarly implanted into the dorsal neck region to record the
electromyogram (EMG). All the electrodes were socketed into an
electrode pedestal (MS363; PlasticsOne, Roanoke, VA, USA), which
was then ﬁxed to the skull using a combination of dental acrylic
resin and alpha-cyanoacrylate adhesive. The electrode-implanted
rats were then singly housed and allowed to recover for more
than 5 days before the qEEG or polysomnogram recordings.
2.4.2. EEG recording for measurement of gamma band oscillation
power
The qEEG recording was performed as described previously (16).
Cortical EEG recordings and drug administrations were performed
under freely moving and unrestrained conditions. Rats were indi-
vidually transferred to an acrylic chamber (30 cm width  30 cm
length  35 cm height) placed within an electrically shielded
sound-proof box and were tethered to a lead wire connected to a
slip-ring commutator (SPM-15-6P; Hikari Denshi, Tokyo, Japan).
The EEG signals were ampliﬁed (20,000 times) and bandpass-
ﬁltered (0.5e1000 Hz) using a biophysical ampliﬁer (AB-611J;
Nihon Kohden, Tokyo, Japan), digitized at a sampling rate of 2.5 kHz
with an analog-to-digital converter (AD16-16U(PCI)EH; Contec,
Osaka, Japan), and recorded using the data acquisition program
VitalRecorder® (Ver. 1.3; Kissei Comtec, Matsumoto, Japan). After a
baseline EEG recording for 30 min in parallel with the acclimation
of the animal to the measurement environment, TASP0443294 or
the vehicle was orally administered, followed 120 min later by the
subcutaneous administration of ketamine at a dose of 5 mg/kg. The
EEG recording was continued for 120 min after the administration
of ketamine. The animals were repeatedly used for the EEG
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terval to ensure drug washout.
The EEG data were individually analyzed off-line with the data
analysis program SleepSign® (Ver. 3.0; Kissei Comtec, Matsumoto,
Japan). After digital ﬁltering (0.5e200 Hz bandpass), a fast Fourier
transformation was performed for each 4-s epoch for a power
spectrum analysis. The total power in the gamma band frequency
(30e80 Hz) was averaged for 1-min bins and was normalized with
the mean value of the 30-min baseline recordings to plot the time
course. The area under the curve (AUC) for the gamma power
change for 120 min after the administration of TASP0443294 and
for 60 min after the ketamine injection were calculated to evaluate
the effects of TASP0443294 on the baseline gamma power and the
ketamine-increased gamma power, respectively. Under the same
condition, subcutaneous administration of LY379268 at a dose of
1 mg/kg signiﬁcantly inhibited ketamine-induced gamma hyper-
activities in rats (16).
2.4.3. Polysomnogramrecordings for the determinationof sleep stage
The polysomnogram recordings were performed in the same
recording environment as the above qEEG recordings. Rats were
acclimated to the measurement environment under freely moving
and unrestrained conditions (lighting period: 07:00 to 19:00, free
access to food and water) for 16e19 h before drug administration.
The polysomnogram (cortical EEG and EMG) was recorded from
06:00 to 15:00 on the administration day. TASP0443294 was
perorally administered between 10:50 and 11:00. The EEG and EMG
signals were ampliﬁed (20,000 times) and band-passed (EEG,
0.5e30 Hz; EMG, 15e1000 Hz) using a biophysical ampliﬁer (AB-
611J; Nihon Kohden, Tokyo, Japan), digitized at a sampling rate of
1024 Hz with an analog-to-digital converter (AD16-16U(PCI)EH;
Contec, Osaka, Japan), and recorded using the data acquisition
program VitalRecorder® (Ver. 1.3; Kissei Comtec, Matsumoto,
Japan). The animals were repeatedly used for the polysomnogram
recording a maximum of three times after a more than 7-day in-
terval to ensure drug washout.
The polysomnogram was analyzed off-line using the data anal-
ysis program SleepSign® (Ver. 3.0; Kissei Comtec, Matsumoto,
Japan). The sleepewake states were classiﬁed in each 8-s epoch as
wakefulness, non-rapid eye movement (NREM) sleep, and REM
sleep by a visual veriﬁcation based on the EEG and EMG patterns
according to a previous report (17). Each state was characterized as
follows: wakefulness, high EMG amplitude and low EEG amplitude;
NREM sleep, low EMG amplitude and high EEG amplitude with a
high-power density in the delta band (0.5e4.0 Hz); REM sleep, very
low EMG amplitude and low EEG amplitude with high values in the
theta band (4.0e8.0 Hz). The cumulative period of REM sleep
during 2 h after the drug administration was calculated and was
presented as a percentage of all the states. Under the same condi-
tion, peroral administration of paroxetine at a dose of 3 mg/kg
signiﬁcantly decreased the duration of REM sleep in rats.
2.4.4. Drugs
TASP0443294 was synthesized at Taisho Chemistry Labora-
tories. Methamphetamine hydrochloride (methamphetamine) was
purchased from Dainippon Sumitomo Pharma Co., Ltd. (Osaka,
Japan). [35S]GTPgS (speciﬁc radioactivity: 46.25 TBq/mmol) was
purchased from PerkinElmer Life Science (Boston, MA, USA).
MK-801 hydrogen maleate (MK-801) was purchased from Sigma-
eAldrich (St. Louis, MO, USA). Ketamine was purchased as veteri-
nary Ketalar® 50 from Sankyo Yell Pharmaceutical Co., Ltd. (Tokyo,
Japan). LY341495 was purchased from Tocris Bioscience (Bristol,
UK). TASP0443294 was suspended in 0.5% methylcellulose for
peroral administration for the in vivo studies and was dissolved in
polyethylene glycol 400 for intravenous administration in thepharmacokinetic study. Methamphetamine and MK-801 were dis-
solved in saline for subcutaneous and intraperitoneal administra-
tion, respectively. Ketamine was diluted in saline for subcutaneous
administration. LY341495 was dissolved in 66.6 mM phosphate
buffer (pH 8.0) for intraperitoneal administration. The volume of
administration was 2 mL/kg. The dose selections for all the drugs
were based on previous reports (14,16) and our preliminary studies.
2.4.5. Data analysis
For the in vitro experiments, data analyses were performed
using GraphPad Prism 5 from GraphPad Software Inc. (San Diego,
CA, USA). The concentrationeeffect curves for [35S]GTPgS binding
were ﬁtted using nonlinear regression analysis. All the statistical
analyses were performed using SAS software (SAS Institute Japan,
Tokyo, Japan). The effects of TASP0443294 on the time course plot
were analyzed using a two-way repeated-measures analysis of
variance (ANOVA). Datawere analyzed using the Student's t-test, or
a one-way ANOVA followed by Dunnett's test and TukeyeKramer
test. A value of P < 0.05 was regarded as signiﬁcant.
3. Results
3.1. In vitro proﬁles of TASP0443294
Glutamate produced an increase in [35S]GTPgS binding in CHO
cells expressing the human or rat mGlu2 receptor in a concentra-
tion dependent fashion, and the glutamate EC50 values for human
and rat mGlu2 receptors were calculated to be 5.4 and 8.2 mM,
respectively. The EC50 values for potentiation by TASP0443294 on
glutamate-increased [35S]GTPgS binding at the human and rat
mGlu2 receptor in the presence of an EC20-equivalent concentra-
tion of glutamate (1 mM) were estimated to be 277 and 149 nM,
respectively (Fig. 2A, B and Table 1). The maximal responses in
human and rat mGlu2 receptors, compared with the response of
1 mM glutamate, were increased to 102% and 132% upon the
addition of TASP0443294, respectively (Table 1). Of note,
TASP0443294 enhanced the response induced by glutamate,
shifting the glutamate concentration response curve both upward
and leftward (Fig. 2C). In contrast, TASP0443294 did not alter basal
[35S]GTPgS binding at the rat mGlu2 receptor at a concentration of
up to 10 mM (data not shown). Moreover, TASP0443294 did not
affect the response to glutamate (100 nM) in [35S]GTPgS binding to
membranes expressing human mGlu3 receptor (Table 1), whereas
glutamate increased [35S]GTPgS binding in a concentration
dependent fashion, with an EC50 value of 286 nM. In addition,
TASP0443294 did not potentiate glutamate-increased [35S]GTPgS
binding in CHO cells expressing the human mGlu8 receptor at a
concentration of up to 10 mM (data not shown).
3.2. Pharmacokinetic study in rats
The results of the pharmacokinetic study, including the plasma
concentrations after the intravenous administration of
TASP0443294 in rats, are shown in Fig. 3. TASP0443294 had a
1.3 ± 0.1 h half-life, with a volume of distribution of 1.18 ± 0.04 L/kg
and a plasma clearance of 0.64 ± 0.05 L/h/kg. The plasma concen-
trations of TASP0443294 at 0.5, 1, 2, and 3 h after the peroral
administration of TASP0443294 are shown in Table 2A. The Tmax
was observed at 2 h after the administration of TASP0443294.
Therefore, for the in vivo study, TASP0443294 was perorally
administered 2 h prior to the test. The plasma, brain and CSF con-
centrations of TASP0443294 at 2.5 h after the peroral administra-
tion of TASP0443294 at doses of 3, 10, and 30 mg/kg in rats are
shown in Table 2B. In rats, the plasma, brain and CSF concentrations
of TASP0443294 increased in a dose-dependent fashion.
Fig. 2. The concentrationeeffect curves for TASP0443294 on the binding of [35S]GTPgS at an EC20-equivalent concentration of glutamate in the human mGlu2 (A) and rat mGlu2
receptors (B). The concentrationeeffect curves for TASP0443294 on the concentrationeresponse curve of the [35S]GTPgS binding by glutamate (C). Data are expressed as percentage
of the maximal response to glutamate and are mean ± S.E.M. in the case of 3 experiments, each done in duplicate.
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rearing activities in rats
Subcutaneous administration of methamphetamine at a dose of
1mg/kg signiﬁcantly increased locomotor (all P < 0.01) (Figs. 4A, 5A
and 5B) and rearing (all P < 0.01) (Figs. 4C, 5C and 5D) activities.
TASP0443294 at doses of 30 and 100 mg/kg signiﬁcantly inhibited
the locomotor [F(3,28) ¼ 3.97, P < 0.05] (P < 0.01) (Fig. 4A),
[F(2,27) ¼ 5.49, P < 0.01] (P < 0.05) (Fig. 5A) and rearing
[F(3,28) ¼ 3.94, P < 0.05] (P < 0.05) (Fig. 4C), [F(2,27) ¼ 10.25,
P < 0.01] (P < 0.01) (Fig. 5C) activities elicited by the subcutaneous
administration ofmethamphetamine. In contrast, TASP0443294 did
not affect spontaneous locomotor and rearing activities up to a dose
of 100 mg/kg [F(3,28) ¼ 1.7, P > 0.05] (Fig. 4B) and [F(3,28) ¼ 0.67,
P > 0.05] (Fig. 4D). In addition, pretreatment with the mGlu2/3
receptor antagonist LY341495 at a dose of 3 mg/kg signiﬁcantly
blocked the effect of TASP0443294 on methamphetamine-induced
locomotor [F(2,27) ¼ 5.49, P < 0.01] (P < 0.05) (Fig. 5A) and rearing
[F(2,27) ¼ 10.25, P < 0.01] (P < 0.05) (Fig. 5C) hyperactivities, indi-
cating that the stimulation of the mGlu2 receptor mediates the ef-
fect of TASP0443294 on locomotor and rearing activities. Of note,Table 1
Functional activity of TASP0443294 at human/rat recombinant mGlu2 receptors and
human recombinant mGlu3 receptor in the presence of glutamate.
Activity in presence of glutamate
EC50 (nM) Emax (%)
Human mGlu2 277 (182e425) 102 (101e102)
Rat mGlu2 149 (120e185) 132 (123e140)
Human mGlu3 >10,000
Glutamate is used at its EC20 and EC40 concentrations for mGlu2 and mGlu3 re-
ceptor, respectively. Values are an average of 3 experiments. Numbers in paren-
theses indicated 95% conﬁdence intervals.LY341495 did not affect methamphetamine-induced locomotor and
rearing hyperactivities at the doses used in the present study
[F(2,21) ¼ 0.08, P > 0.05] (Fig. 5B) and [F(2,21) ¼ 0.12, P > 0.05]
(Fig. 5D).
3.4. MK-801-induced social memory deﬁcits in rats
The intraperitoneal administration of MK-801 at a dose of
0.1 mg/kg signiﬁcantly increased the ratio of investigation duration
(P < 0.01) (Fig. 6), indicating that MK-801 impaired short-term
social memory. TASP0443294 at a dose of 30 mg/kg signiﬁcantlyFig. 3. Pharmacokinetic proﬁles of TASP0443294 after intravenous administration in
rats. Plasma concentrations of TASP0443294 were measured at 5, 15 and 30 min and 1, 2,
4 and 8 h after administration. Three animals were used for this study. TASP0443294 at a
dose of 0.25 mg/kg was administered intravenously in rats. Values are mean ± S.D.
Table 2
Brain and plasma concentrations of TASP0443294 in rats after peroral administra-
tion. A: Pharmacokinetic proﬁles of TASP0443294 after peroral administration. B:
Brain, plasma and CSF concentrations 2.5 h after administration of TASP0443294.
A
3 mg/kg, p.o. Time
0.5 h 1 h 2 h 3 h
Plasma (ng/mL) 384 ± 65 531 ± 122 593 ± 100 458 ± 157
B
Dose (mg/kg, p.o.) Brain (ng/g) Plasma (ng/mL) CSF (ng/mL)
3 835 ± 320 441 ± 200 26 ± 11
10 3830 ± 1010 1650 ± 343 94 ± 29
30 8400 ± 3700 3720 ± 1900 213 ± 80
A: Plasma concentrations of TASP0443294 were measured at 0.5, 1, 2, and 3 h after
administration. TASP0443294 at a dose of 3 mg/kg was administered perorally in
rats. B: TASP0443294 at doses of 3, 10, and 30 mg/kg was administered perorally in
rats. Brain, plasma and CSF samples were collected 2.5 h after administration. Values
are mean ± S.D., n ¼ 3 animals per each group. Brain: brain concentration, Plasma:
plasma concentration, CSF: CSF concentration.
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MK-801 [F(2,52) ¼ 4.44, P < 0.05) (P < 0.01) (Fig. 6).
3.5. Ketamine-induced gamma hyperactivities in the prefrontal
cortex of rats
In the time course analyses, a two-way repeated measures
ANOVA demonstrated that TASP0443294 (10e30 mg/kg) showedFig. 4. Effects of TASP0443294 on methamphetamine-induced locomotor (A) and rearing (
Data represent the mean ± S.E.M., n ¼ 8 animals per each group. ##P < 0.01, compared with
response to vehicle þ methamphetamine (Dunnett's test).signiﬁcant doseetime interactions [F(478,5019)¼ 1.24, P < 0.01] on
the ketamine-increased gamma power (Fig. 7A). TASP0443294 at a
dose of 30 mg/kg signiﬁcantly inhibited the ketamine-increased
gamma power (P < 0.05) (Fig. 7B).
3.6. REM sleep in rats
TASP0443294 decreased the duration of REM sleep during 2-h
period, compared with the vehicle, in a dose-dependent fashion
[F(2,30) ¼ 6.46, P < 0.05]. The effect of TASP0443294 was statisti-
cally signiﬁcant at a dose of 10 mg/kg (P < 0.01) (Fig. 8).
4. Discussion
In this study, we demonstrated that an orally active mGlu2
receptor positive allosteric modulator, TASP0443294, improved
methamphetamine-induced hyperlocomotion and MK-801-
induced social memory deﬁcits. Moreover, TASP0443294 attenu-
ated ketamine-induced basal gamma hyperactivity in the prefrontal
cortex and decreased the duration of REM sleep. The present results
not only conﬁrm the previous ﬁndings that mGlu2 receptor positive
allosteric modulators exert antipsychotic effects in animal models,
but show that mGlu2 receptor positive allosteric modulators can
improve the same neural circuit deﬁcits in the same manner as
orthosteric mGlu2/3 receptor agonists.
Regarding the glutamate-induced increase in [35S]GTPgS bind-
ing, TASP0443294 exerted similar potentiated activities and a
maximal response for human and rat mGlu2 receptors, with EC50C) hyperactivities and on spontaneous locomotor (B) and rearing (D) activities in rats.
response to vehicle þ saline (Student's t-test). *P < 0.05, **P < 0.01, compared with the
Fig. 5. Effects of LY341495 on TASP0443294 inhibition on methamphetamine-induced locomotor (A) and rearing (C) hyperactivities and effects of LY341495 on methamphetamine-
induced locomotor (B) and rearing (D) hyperactivities in rats. Data represent the mean ± S.E.M., n ¼ 8e10 animals per each group. ##P < 0.01, compared with response to
vehicle þ vehicle þ saline or vehicle þ saline (Student's t-test) or. *P < 0.05, **P < 0.01, compared with the response to vehicle þ vehicle þmethamphetamine (TukeyeKramer test).
$P < 0.05, compared with the response to vehicle þ TASP0443294 þ methamphetamine (TukeyeKramer test).
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respectively, without affecting the basal [35S]GTPgS binding. On the
other hand, TASP0443294 did not affect the glutamate-induced
increase in [35S]GTPgS binding for the human mGlu3 receptor.
These ﬁndings suggested that TASP0443294 is a selective positive
allosteric modulator at the mGlu2 receptor among group II mGlu
receptors. Moreover, pharmacokinetic studies revealed that
TASP0443294 penetrated into the brain and CSF in quantities suf-
ﬁcient to exert pharmacological effects after peroral administra-
tion. Therefore, TASP0443294 might be a useful pharmacological
tool for studying the function of mGlu2 receptors in vivo.
The antipsychotic effects of TASP0443294 were evaluated using
two animal models of schizophrenia, methamphetamine-induced
locomotor hyperactivity and MK-801-impaired social memory.
Psychostimulant-induced hyperlocomotion is considered to be an
animal model for the positive symptoms of schizophrenia (18),
while the induction of social memory impairment by a non-
competitive NMDA receptor antagonist, MK-801, in rats is consid-
ered to be useful as an animal model for evaluating improvements
in cognitive dysfunction in schizophrenia (14). In the present study,
TASP0443294 reversed methamphetamine-induced locomotor
hyperactivity and improved MK-801-induced social memory
impairment in rats. These results further support our previousﬁndings and those of others that both mGlu2/3 receptor agonists
and mGlu2 receptor positive allosteric modulators are effective in
these models (9,11,19). However, some discrepancies exist among
mGlu2 receptor positive allosteric modulators. For example, an
mGlu2 receptor positive allosteric modulator, LY487379, attenu-
ated amphetamine-induced locomotor hyperactivity as well as
spontaneous locomotor activity in mice (9), while TASP0443294
did not affect spontaneous locomotor activity. Moreover, another
mGlu2 receptor positive allosteric modulator, 3'-[[(2-cyclopentyl-
2,3-dihydro-6,7-dimethyl-1-oxo-1H-inden-5-yl)oxy]methyl]-[1,1'-
biphenyl]-4-carboxylic acid (BINA), reportedly did not reverse
amphetamine-induced hyperlocomotion (10). Although these dif-
ferences may be ascribed to differences in the mode of potentiation
and modest intrinsic agonist activity at the mGlu2 receptor, the
reason for these differences among mGlu2 receptor allosteric
modulators remains unclear. Different classes of positive allosteric
modulators may have different in vivo effects as a result of differ-
ential actions on receptors (10,20). Thus, TASP0443294, which is
structurally distinct from LY487379 and BINA, may be useful for
delineating the molecular mechanisms of the above-mentioned
differences among mGlu2 receptor positive allosteric modulators.
Of note, the effect of TASP0443294 on methamphetamine-induced
locomotor hyperactivity is not an off-target effect, but rather
Fig. 6. Effects of TASP0443294 on MK-801-induced social memory deﬁcits in rats. Data
represent mean ± S.E.M. n ¼ 18e19 animals per each group. ##P < 0.01 compared with
response to vehicle þ saline (Student's t-test). **P < 0.01 compared with response to
vehicle þ MK-801 (Dunnett's test). Fig. 8. Effects of TASP0443294 on duration of REM sleep in rats for 2 h after oral
administration. Data represent the mean ± S.E.M. n ¼ 11e12 animals per group.
**P < 0.01, compared with the response to vehicle treatments (Dunnett's test).
H. Hikichi et al. / Journal of Pharmacological Sciences 127 (2015) 352e361 359mediates the stimulation of the mGlu2 receptor, since the effect
of TASP0443294 was completely blocked by an mGlu2/3
receptor antagonist, LY341495, at a dose that did not affect
methamphetamine-induced locomotor hyperactivity by itself.
However, in addition to the mGlu2/3 receptor, LY341495 also hasFig. 7. Effects of TASP0443294 on ketamine-induced elevations in gamma power in
rats. (A) Time course changes in gamma power in the frontal cortex of rats. Values are a
percentage of the baseline value, which corresponds to the mean value before drug
administration. The open arrow indicates the timing of TASP0443294 administration,
and the closed arrow indicates ketamine administration. (B) AUC values
(120e180 min) for the gamma power in the rat frontal cortex after the administration
of ketamine. Data represent the mean ± S.E.M. n ¼ 8 animals per group. *P < 0.05,
compared with the response to vehicle treatments (Dunnett's test).antagonistic activities at the mGlu7 and mGlu8 receptors (21).
Because we have not yet tested the activity of TASP0443294 at the
mGlu7 receptor, a possible role of the mGlu7 receptor in the in vivo
effect of TASP0443294 cannot be fully ruled out.
In the present study, the neurophysiological effects of
TASP0443294were evaluated using two EEG recordings: REM sleep
and ketamine-induced gamma oscillation. EEG is considered to be a
translational biomarker for targets and compounds, since EEG can
be recorded in both humans and rodents. The present result that
TASP0443294 reduced the amount of REM sleep in rats is consis-
tent with previous ﬁndings that orthosteric mGlu2/3 receptor ag-
onists and other mGlu2 receptor positive allosteric modulators,
such as BINA, THIIC and JNJ-40068782, reduced the amount of REM
sleep in rats (12,22e24). Thus, REM sleep as observed on a poly-
somnogram may be useful as a sensitive biomarker for mGlu2 re-
ceptor activation. Glutamate levels reportedly increase during REM
sleep in the orbitofrontal and cerebral cortex of rats (25,26).
Therefore, the inhibition of glutamate release elicited by the stim-
ulation of mGlu2 receptors may result in a decrease in the duration
of REM sleep, and mGlu2 receptor positive allosteric modulators
may share the same neuronal mechanisms for their effects on the
reduction in REM sleep and their antipsychotic actions.
Aberrant gamma oscillations have been reported to be associ-
ated with the symptoms of schizophrenia (27,28). The adminis-
tration of NMDA-receptor antagonists reportedly increase basal
gamma oscillation on EEG recording of activity in the prefrontal
cortex, presumably as a result of the disinhibition of pyramidal
neurons through a reduction in g-aminobutyric acid (GABA) in-
terneurons activities (16), which may represent the neuronal
mechanism for the glutamate hypothesis explaining schizophrenia
(29). In the present study, TASP0443294 inhibited the cortical
spontaneous gamma hyperactivity elicited by ketamine in freely
moving rats. In a preliminary study, TASP0443294 slightly but
dose-dependently reduced the baseline of gamma oscillation po-
wer with the same effective doses (data not shown). However,
TASP0443294 inhibited the trough-to-peak response of ketamine,
although it was not statistically signiﬁcant (data not shown). Given
H. Hikichi et al. / Journal of Pharmacological Sciences 127 (2015) 352e361360that the mGlu2/3 receptor agonist LY379268 inhibits both
ketamine-induced increases in gamma oscillations and reduces
spontaneous gamma oscillations in the cortex of rats (16,30), the
activation of the mGlu2 receptor may play a role in the modulation
of gamma oscillations. Of note, this is the ﬁrst result to show that
the attenuation of NMDA receptor antagonist-induced aberrant
gamma oscillations by an mGlu2/3 receptor agonist is mediated
through the stimulation of the mGlu2 receptor, and that mGlu2
receptor positive allosteric modulators may improve the same
neuronal circuit deﬁcits possibly observed in schizophrenia as do
orthosteric mGlu2/3 receptor agonists. The hippocampus (31),
amygdala (32), and prefrontal cortex (33) are thought to be
involved in social memory in rodents. Therefore, the improvement
in social memory impairment induced by an mGlu2 receptor pos-
itive allosteric modulator may be partially attributable to the sup-
pression of the aberrant excitability of pyramidal neurons through
GABAergic disinhibition, at least in the prefrontal cortex. It would
be interesting to compare the effect of mGlu2 receptor positive
allosteric modulators on ketamine-increased gamma oscillation
and locomotor activity in future studies.
In summary, the orally active mGlu2 receptor positive allosteric
modulator TASP0443294 exhibits antipsychotic-like activities in
animal models. TASP0443294 inhibited not only dopamine-related,
but also NMDA receptor-related abnormal behaviors that are
considered to be animal models for the positive symptoms and
cognitive dysfunction of schizophrenia, respectively. Moreover,
because TASP0443294 improved aberrant gamma oscillations,
gamma oscillations, in addition to REM sleep, may be useful as
translatable biomarkers for mGlu2 receptor positive allosteric
modulators. In addition, TASP0443294may provide a useful tool for
examining the usefulness of mGlu2 receptor positive allosteric
modulators for the treatment of schizophrenia as well as the
neuronal mechanisms underlying the antipsychotic effects of
mGlu2 receptor positive allosteric modulators.Conﬂict of interest
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